Portola Pharma (PTLA) Tops Q4 EPS by 17c

Portola Pharma (NASDAQ: PTLA) reported Q4 EPS of ($0.95), $0.17 better than the analyst estimate of ($1.12). Revenue for the quarter came in at $13.69 million versus the consensus estimate of $3.98 million.

2017 Annual Financial GuidanceFor the fiscal year 2017, Portola expects total GAAP operating expenses to be between $323 million and $344 million. For the fiscal year 2017, Portola expects total pro-forma operating expenses to be between $290 million and $310 million, excluding stock-based compensation. These expenses will be primarily for manufacturing of both andexanet and betrixaban, support of ongoing clinical trials and preparation for the potential commercial launches of betrixaban and AndexXa.

For earnings history and earnings-related data on Portola Pharma (PTLA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• SanDisk upgraded at JPMorgan after investor day; shares climb